Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine.
In March 2020, as the pandemic was sweeping the globe and establishing roots in Australia, the Complex Systems Centre at the University of Sydney modelled how varying rates of social distancing could affect the spread of the COVID-19 pandemic across a very diverse Australian population.
The COVID-19 Research Symposium, hosted by the Mount Sinai Clinical Intelligence Center (MSCIC), is a one-day comprehensive review of advances in research by the Mount Sinai Health System to better understand and treat the coronavirus known as COVID-19.
Half of vaccines are wasted annually because they aren’t kept cold. Michigan Tech and UMass Amherst chemical engineers have discovered a way to stabilize viruses in vaccines with proteins instead of temperature.
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses (HPV) has emerged. It is based on a highly specific diagnostic test that appears to indicate cancer, and predict its course, from just a pinprick of blood.
Published: November 10, 2020 | 3:47 pm | SHARE: There may be good news on the horizon regarding a COVID-19 vaccine.Pfizer and partner BioNTech reported that their trial vaccine appears to have a 90 percent efficacy rate, meaning that test subjects who received a vaccine experienced 90 percent fewer cases of symptomatic COVID-19 than those who received a placebo.
The first COVID-19 vaccines could be authorised as early as the start of 2021.
Newborns and young infants are particularly susceptible to the flu and are six times more likely to die from the infection than older children. Currently there is no flu vaccine available for babies less than 6 months old.
ACTIV-2 will evaluate the safety and efficacy of investigational treatments for adults who have COVID-19, but do not require hospitalization. ACTIV-2 is a randomized, blinded, controlled study that tests a variety of new agents against placebo. This approach allows promising investigational agents to be added and removed over the course of the study.
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
Canada's National Advisory Committee on Immunization (NACI) recommends vaccinating key populations, such as people at risk of severe illness or death, those at risk of transmitting the virus and essential workers, during the initial rollout of a COVID-19 vaccine in Canada.
The state of Iowa has designated $2 million in federal CARES Act funding to support university research and development of a nanovaccine to protect against COVID-19 infections. Researchers at Iowa State University and the University of Iowa will work together on a needle-free, single-dose nanovaccine.
A Phase III clinical trial to assess if a potential vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (UTHealth) in collaboration with Memorial Hermann-Texas Medical Center.
The University of Chicago Medical Center will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, ENSEMBLE trial, to evaluate the safety and efficacy of the Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.
In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.
More than a dozen U.S. Immigration and Customs Enforcement (ICE) detention centers experienced large, repeated outbreaks of vaccine-preventable illnesses in the last three years, according to a new study by researchers at UC San Francisco.
Wistar scientists have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein.
University Hospitals and Case Western Reserve University announcement that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca (LSE/STO/NYSE: AZN).
Dr. Edward Jones-Lopez, joins a Newswise Live Expert Panel on Thursday Oct. 29, from 3-4 PM EDT to discuss the AstraZenea COVID-19 vaccine trial.
Study examines “personal belief exemptions” (PBEs) to childhood vaccine requirements among certain communities in California.
Nationalistic behaviour by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organisation RAND Europe.
Researchers at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine have been jointly awarded a major grant from the National Cancer Institute, part of the National Institutes of Health, to set up a center for research on the human serological immune response to SARS-CoV-2, the coronavirus that causes COVID-19.
One of the proteins on the virus – located on the characteristic COVID spike – has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” That is, he said, antibodies against this part of the virus have the potential to the neutralize the virus.
As the race for a COVID-19 vaccine intensifies, health care officials are reminding the public not to forget another important vaccine this fall: the flu shot. Flu season in the U.S. technically began in September, with illnesses expected to peak in December and February, according to the Centers for Disease Control (CDC). Less than half of Americans received a flu vaccine during the 2019-2020 flu season, and a staggering 405,000 hospitalizations and 22,000 deaths were attributed to influenza.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
Edward Jones-Lopez, MD, MS, a Keck Medicine of USC infectious diseases expert and investigator of one of the Operation Warp Speed vaccine clinical trials, answers the questions on everyone’s mind.
Two Rutgers New Jersey Medical School pediatricians discuss the importance of keeping children and adults up to date with immunizations during the coronavirus crisis.
An immunology researcher in Canada has found a simple solution to prevent infections in children with lactic acidosis: get them vaccinated.
A research team from the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), the Barcelona Institute for Global Health (ISGlobal), the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine (LSHTM), and Georgetown University Law School announced today that Nature Medicine has published their research revealing potential global hesitancy to accept a COVID-19 vaccine.
If an initial COVID-19 vaccine is about as effective as a flu shot, uptake by the American public may fall far short of the 70% level needed to achieve herd immunity, new Cornell research suggests.
The National Foundation for Infectious Diseases (NFID) issued a new Call to Action report detailing the risks of co-infection with influenza (flu) and COVID-19 in adults with chronic health conditions, and the importance of flu vaccination during the 2020-2021 season.
University of Chicago Medicine infectious diseases expert Dr. Allison Bartlett explains what to know to stay safe this winter from both influenza and COVID-19.
A new article by Columbia Mailman School researchers Jeffrey Shaman and Marta Galanti explores the potential for the COVID-19 virus to become endemic, a regular feature producing recurring outbreaks in humans.
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.
The COVID-19 pandemic will remain the dominant topic for Americans in nearly every aspect of their lives in 2021, according to a survey in the USC Center for Public Relations’ annual Relevance Report. When asked about news they will consume, 44% of Americans say the COVID-19 vaccine will be the topic they are most interested in hearing and reading about within the next year. However, despite the challenges faced in 2020, Americans remain hopeful about the future, with 37% choosing “fingers crossed” as the emoji that best expresses their feelings about the new year — more than twice the number of respondents who said they were worried.
People who have recovered from COVID-19, and their close contacts, could hold the key to understanding how immunity to the disease develops, how long it lasts and what happens when immunity is lost.
A team of researchers at the University of Chicago have developed a self-assembling nanoparticle to create a toolbox for treating infections such as Toxoplasma gondii, a serious parasitic infection.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
New research in Clinical and Translational Immunology, provides a clearer picture of the protective antibodies induced by SARS-CoV-2 and their role in serious illness and what’s needed for full protection.
A COVID-19 vaccine candidate that underwent extensive preclinical testing this spring and summer shows potent preclinical immune responses — including several that distinguish it from other COVID-19 vaccine approaches — according to a preprint deposited in the BioRxiv repository.
Vaccines currently being developed for Covid-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.
Rutgers medical schools' Dean discusses the importance of Black and Latinx representation in clinical trial studies and the critical steps the medical community can take in rebuilding the trust in minority communities by more transparency and continuous education
Media invited to live Q&A on Oct 7th, 2pm EDT
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right